The National People's Congress of China issued the 2nd Revision of Drug Administration Law

The new revised Drug Administration Law of China will be effective since December 01, 2019

On August 26, 2019, the 2nd revised Drug Administration Law of China was approved by the 12th Session of the Standing Committee of China’s National People's Congress, pursuant to Presidential Order No. 31. Effective December 1, 2019, the amended law focuses on people’s health, risk management, addressing problems during the drug development period, and the quality of drugs. Among other things, the amended law improves management systems in order to support drug innovation and optimize clinical trial management, including priority reviews and a conditional approval system. More details about the key changes in this major overhaul of the law can be found online in Chinese at the moment.

Read more online
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /